[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vitiligo-generalized\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vitiligo-generalized":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100597210","early-phase-1-comparison-of-efficacy-and-safety-psoralen-combined-with-ultraviolet-a-puva-vs-tofacitinib-in-the-treatment-of-generalized-vitiligo-100597210",false,"NCT07055529","Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.","(PUVA)","Inclusion Criteria:\n\n* • Patients of either gender aged 18-60 years, diagnosed with generalized vitiligo (depigmentation affecting more than 10% of the body surface area).\n\n  * Stable vitiligo (no new lesions or progression of existing lesions in the last three months).\n\nExclusion Criteria:\n\n* Patients with a history of photosensitivity or allergies to Psoralen or Tofacitinib in order to prevent adverse reactions that could compromise patient safety and interfere with treatment efficacy assessment.\n* Pregnant or lactating women in order to ensure fetal and neonatal safety, as the effects of Psoralen and Tofacitinib on pregnancy and breastfeeding are not well studied and could pose potential risks.",true,"ALL","18 Years","60 Years",{"count":21,"type":22},64,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","This study aims to compare the efficacy and safety of PUVA versus Tofacitinib in the treatment of generalized vitiligo. Given the high prevalence of vitiligo in Pakistan and the significant psychosocial impact on patients, particularly in Peshawar, this study will provide valuable insights into optimal treatment strategies.",[28],"Vitiligo, Generalized","NOT_YET_RECRUITING","2026-01-29",{"date":32,"type":33},"2026-01-30","ACTUAL",{"date":35,"type":22},"2026-06-01",{"date":37,"type":22},"2026-12-31",{"name":39,"class":40},"Hayat Abad Medical Complex, Peshawar","OTHER_GOV",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":41},"100575173","phase-2-vitiligo-new-treatment-and-serum-s100b-100575173","NCT06768840","Vitiligo, New Treatment and Serum s100B","Serum s100B in Generalized Vitiligo and Its Relation to Oral Baricitinib, Narrow Band Ultraviolet (B) Therapy","Inclusion Criteria:\n\n* active generalized vitiligo patients with body surface area involved \\>5% excluding hands and feet\n* no systemic treatment for vitiligo for the last 3 months or topical treatment received for the last 4 weeks.\n\nExclusion Criteria:\n\n* acrofacial, acral, segmental or mucosal vitiligo\n* patients on another immunosuppressive agent\n* patients have other skin conditions (psoriasis, SLE, alopecia areata) that would interfere with evaluations of the effect of study medication on vitiligo.\n* patients who suffered from systemic diseases affecting S100B (e.g. Subarachnoid hemorrhage, Alzheimer disease and inflammatory diseases) or from other dermatological diseases affecting S100B level (e.g. malignant melanoma)\n* Patients immunocompromised, uncontrolled arterial hypertension, clinically serious viral, bacterial, fungal, or parasitic infection, anemia, history of thromboembolic event, cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, lymphoproliferative disease, neurological, or neuropsychiatric disorders or any other serious and\u002For unstable illness.\n* Pregnancy and lactation.","10 Years","75 Years",{"count":52,"type":22},50,[54,55],"PHASE2","PHASE3","vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem.\n\nMultiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors",[28],[59,60,61,62,63,64],"vitiligo","jak inhibitor","baricitinib","oral mini pulse","dexamethasone","phototherapy","RECRUITING","2025-01-06",{"date":68,"type":33},"2025-01-10",{"date":70,"type":33},"2024-10-02",{"date":72,"type":22},"2025-10",{"name":74,"class":75},"South Valley University","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100558049","gasdermin-d-expression-in-generalized-vitiligo-patients-after-narrow-band-ultraviolet-b-therapy-100558049","NCT06546059","Gasdermin D Expression in Generalized Vitiligo Patients After Narrow-band Ultraviolet B Therapy","Inclusion Criteria:\n\n* Patients with stable vitiligo of 6 months duration,\n* Both sex and ages(10-75)\n\nExclusion Criteria:\n\n* pregnancy,\n* lactation,\n* patients under or previous phototherapy,\n* patients on other immunosuppressives,\n* patients receiving topical or systemic therapy like antioxidants and vitamins were kept off treatment for 2 weeks prior to recruitment into the study.",{"count":83,"type":22},40,[85],"NA","The aim of this study is to:\n\n1. Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls.\n2. Evaluation expression of tissue Gasdermin D using immunehistochemstry techniques in patients with generalized vitiligo after narrow band ultraviolet B therapy.\n3. Determine whether there is a relationship between Gasdermin D levels and disease duration and involved body surface area (VISA) in vitiligo patients.",[28],"2024-08-08",{"date":90,"type":33},"2024-08-09",{"date":92,"type":22},"2024-08",{"date":94,"type":22},"2024-11",{"name":74,"class":75}]